Pacira Pharmaceuticals, Inc. to Present at the 27th Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Pacira Pharmaceuticals, Inc. to Present at the 27th Annual Piper Jaffray Healthcare Conference

PARSIPPANY, N.J., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ) today announced that Dave Stack, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 27 th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET on Tuesday, December 1, in New York City. Mr. Stack is expected to present an overview of the company.

A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com . A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.

About Pacira                                                                           

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX ) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com .

Company Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Helaina Secures $45 Million to Innovate Human Protein Nutrition

Updated Category News Views 205

Helaina Secures Major Funding for Nutritional Advancements In a significant move for the biotechnology industry, Helaina, a trailblazer in nutrition, has successfully raised $45 million in Series B funding. This recent round brings the company’s total equity funding to an impressive $83 million. Avidity Partners led this funding initiative, with notable contributions...

Continue Reading
Blue Water Seeks Court Green Light for CITGO $10 Billion Deal

Updated Category News Views 214

Blue Water's Ambitious Move Toward CITGO Acquisition Blue Water Venture Partners, LLC, led by Joseph Hernandez, has initiated a significant legal step by formally requesting the United States District Court’s approval for its ambitious $10 billion bid for CITGO Petroleum Corporation's assets. This pivotal moment is rooted in a strategic bid that aims to reshape the...

Continue Reading
Quaker Houghton Reveals Strong Q3 2025 Financial Performance

Updated Category News Views 167

Quaker Houghton Reports Third Quarter 2025 Outcomes Quaker Houghton (NYSE: KWR), the global leader in industrial process fluids, has showcased its robust performance for the third quarter of 2025. With net sales reaching an impressive $493.8 million, this marks a 7% increase year-over-year, rising from $462.3 million in the same quarter last year. This growth trajectory...

Continue Reading
SMArtX Expands Offerings with Innovative New Investment Strategies

Updated Category News Views 180

Innovative Strategies Expand SMArtX Manager Marketplace In a dynamic move to enrich its Manager Marketplace, SMArtX Advisory Solutions, known for its cutting-edge managed accounts technology, has recently introduced five new strategies from two respected asset management firms. This exciting development now brings SMArtX’s total offerings to an impressive 1,537...

Continue Reading
Kaskela Law Investigates Payoneer Global Inc. for Shareholders

Updated Category News Views 183

Kaskela Law Firm Investigates Payoneer for Its Investors Kaskela Law LLC is currently investigating Payoneer Global Inc. (NASDAQ: PAYO) on behalf of its shareholders. The firm's aim is to uncover any potential violations of securities laws or breaches of fiduciary duty by the company's officers and directors. Details of the Investigation The main focus of this inquiry is...

Continue Reading